Valuation: Axonics, Inc.

Market Cap 3.63B 3.17B 2.93B 2.7B 5.13B 346B 5.22B 34.97B 13.73B 170B 13.62B 13.32B 586B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.9B 2.67B 2.47B 4.68B 316B 4.76B 31.91B 12.53B 156B 12.43B 12.16B 535B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2013-09-30
Director of Finance/CFO 41 2023-10-01
Chief Operating Officer 47 2018-07-31
Director TitleAgeSince
Director/Board Member 69 2018-01-31
Chairman 55 2020-04-28
Director/Board Member 74 2019-04-07
Date Insider Type Main position Quantity % Market Cap.
24-11-14Issuer sale

Chief Financial Officer

43,487 0.0851%
24-11-14Issuer sale

Chairman

32,861 0.0643%
24-11-14Issuer sale

Director

33,194 0.0649%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+41.85% 3.63B
+0.82%+0.99%-16.46%+11.68% 125B
+0.84%+1.15%-1.34%-2.61% 12.77B
-1.52%+2.95%+43.33%+115.86% 9.1B
+4.14%-2.38%-47.99%-72.05% 3.81B
-0.47%-1.34%+22.30%+45.04% 2.7B
+0.61%-7.70%-14.72%-20.20% 1.73B
+0.49%-3.87%-4.88%-25.01% 1.59B
+0.47%+10.24%-62.83%-83.35% 1.48B
Average +0.68%+0.13%-9.18%+1.25% 18.02B
Weighted average by Cap. +0.74%+0.99%-11.93%+14.09%

Financials

2022 2023
Net sales 274M 239M 221M 204M 387M 26.1B 394M 2.64B 1.04B 12.86B 1.03B 1.01B 44.21B 366M 320M 296M 273M 518M 34.94B 527M 3.53B 1.39B 17.21B 1.38B 1.35B 59.18B
Net income -59.7M -52.22M -48.16M -44.48M -84.41M -5.69B -85.83M -575M -226M -2.8B -224M -219M -9.64B -6.09M -5.33M -4.91M -4.54M -8.61M -581M -8.75M -58.69M -23.05M -286M -22.86M -22.36M -983M
Net Debt -348M -304M -281M -259M -492M -33.2B -500M -3.36B -1.32B -16.35B -1.31B -1.28B -56.22B -317M -278M -256M -236M -449M -30.27B -456M -3.06B -1.2B -14.91B -1.19B -1.17B -51.26B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock